SCHEMBL29369754

SCHEMBL29369754

CC(C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)Cc1ccccc1)C(=O)NC(C=O)Cc1ccc(O)cc1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRNA1 P02708 3/20 0.52
CHRNG P07510 3/20 0.52
CHRNB1 P11230 3/20 0.52
CHRND Q07001 3/20 0.52
GRIA1 P42261 1/20 0.52
CASP3 P42574 2/20 0.51
CASP7 P55210 1/20 0.51
CTSB P07858 3/20 0.51
CASP1 P29466 3/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
CTSL P07711 1/20 0.49
CTSS P25774 1/20 0.49
CASP9 P55211 1/20 0.49
REN P00797 1/20 0.46
OPRD1 P41143 2/20 0.46
OPRM1 P35372 1/20 0.46
OPRK1 P41145 1/20 0.46
MMP9 P14780 1/20 0.45
MMP8 P22894 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29538222 0.91 OPRD1 (0.49) CHRNA1CHRNGCHRNB1CHRNDGRIA1
SCHEMBL31010534 0.91 CTSD (0.54) CASP3CASP7CTSBCASP1SMN1; SMN2
SCHEMBL9219464 0.91 CTSD (0.54) CASP3CASP7CTSBCASP1SMN1; SMN2
Tyropeptin A SCHEMBL2808523 0.86 CASP1 (0.50) CASP3CASP7CTSBCASP1SMN1; SMN2
Tyropeptin A SCHEMBL29843181 0.86 CASP1 (0.50) CASP3CASP7CTSBCASP1SMN1; SMN2
Tyropeptin A SCHEMBL2808528 0.86 CASP1 (0.50) CASP3CASP7CTSBCASP1SMN1; SMN2
SCHEMBL29426382 0.86 OPRD1 (0.48) CASP3CASP7CASP1CASP9OPRD1
SCHEMBL30467221 0.82 MMP2 (0.48) CASP3CASP7CASP1CASP9REN
SCHEMBL29434519 0.82 OPRD1 (0.54) GRIA1CTSBCASP1CTSSOPRD1
SCHEMBL622416 0.82 CTSB (0.54) GRIA1CASP3CASP7CTSBCASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119909033-A Esomeprazole magnesium enteric-coated particles and preparation method thereof 江苏海之宏生物医药有限公司 2025-05-02 CN claimed
CN-119652203-A Closed-loop control method for motor 广东晟辉科技股份有限公司 2025-03-18 CN claimed
CN-221042337-U Vehicle-mounted high-power USB charging module 科博达技术股份有限公司 2024-05-28 CN claimed
CN-221042338-U Vehicle-mounted high-power USB data charging module 科博达技术股份有限公司 2024-05-28 CN claimed
CN-220421459-U Vehicle-mounted charging circuit with double USB interfaces 科博达技术股份有限公司 2024-01-30 CN claimed
CN-220234228-U Vehicle-mounted high-power USB data charging module 科博达技术股份有限公司 2023-12-22 CN claimed
CN-116961167-A Vehicle-mounted charging circuit with double USB interfaces 科博达技术股份有限公司 2023-10-27 CN claimed
CN-116683580-A Vehicle-mounted high-power USB charging module 科博达技术股份有限公司 2023-09-01 CN claimed
CN-116683582-A Vehicle-mounted high-power USB data charging module 科博达技术股份有限公司 2023-09-01 CN claimed
CN-116683581-A Vehicle-mounted high-power USB data charging module 科博达技术股份有限公司 2023-09-01 CN claimed
CN-115844854-A Microcapsule type self-suspending theophylline sustained release granule and preparation method thereof 沈阳药科大学 2023-03-28 CN claimed
US-12636361-B2 Smallpox vaccine for cancer treatment CALIDI BIOTHERAPEUTICS (NEVADA), INC. (US) 2026-05-26 US disclosed
EP-4731770-A1 CHIMERIC PROTEINS FOR MODULATING CYTOKINE RECEPTOR ACTIVITY Ablynx NV (BE) 2026-04-29 EP disclosed
EP-3251301-B1 SYSTEM AND METHOD FOR A GLOBAL VIRTUAL NETWORK UMBRA TECH LTD (CN) 2026-04-08 EP disclosed
US-20260019302-A1 SYSTEM AND METHOD FOR A GLOBAL VIRTUAL NETWORK UMBRA TECHNOLOGIES LTD. (CN) 2026-01-15 US disclosed
CN-115212301-A Smallpox vaccine for cancer treatment 卡利迪生物治疗有限公司 2022-10-21 CN disclosed
CN-113285864-B System and method for global virtual network 安博科技有限公司 2022-10-04 CN disclosed
CN-108135996-B Smallpox vaccine for cancer treatment 卡利迪生物治疗有限公司 2022-06-21 CN disclosed
US-20220158867-A1 SYSTEM AND METHOD FOR A GLOBAL VIRTUAL NETWORK UMBRA TECHNOLOGIES LTD. (CN) 2022-05-19 US disclosed
US-11240064-B2 System and method for a global virtual network UMBRA TECHNOLOGIES LTD. (CN) 2022-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12636361-B2 Smallpox vaccine for cancer treatment BMX, TP53, PBK CHRNA1 3268/4885CHRNG 2530/4885CHRNB1 2893/4885
US-20260019302-A1 SYSTEM AND METHOD FOR A GLOBAL VIRTUAL NETWORK STAT4, NECTIN4, STAT3 CHRNA1 2210/4885CHRNG 1676/4885CHRNB1 2413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.